ADIL

In the past six months, Adial Pharmaceuticals' stock has trended down. The company announced a reverse stock split and a public offering. Adial Pharmaceuticals regained compliance with Nasdaq's listing requirement. The company reported its 2025 fiscal year financial results and provided a business update. Adial Pharmaceuticals advanced its IP portfolio with a new U.S. utility patent application for AD04. The company submitted an application to the FDA Commissioner's National Priority Voucher Pilot Program for its AD04 clinical development program. Adial Pharmaceuticals successfully completed the manufacturing of a demonstration batch production for AD04. The company commended Congress on the introduction of bipartisan legislation aimed at expanding access to emerging AUD therapies for veterans. Adial Pharmaceuticals reported a net loss and stated that its existing cash is expected to fund operations into the second half of 2026, raising doubt about its ability to continue as a going concern.